Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

1,242 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Therapy for Stage IV Non-Small-Cell Lung Cancer Without Driver Alterations: ASCO and OH (CCO) Joint Guideline Update.
Hanna NH, Schneider BJ, Temin S, Baker S Jr, Brahmer J, Ellis PM, Gaspar LE, Haddad RY, Hesketh PJ, Jain D, Jaiyesimi I, Johnson DH, Leighl NB, Phillips T, Riely GJ, Robinson AG, Rosell R, Schiller JH, Singh N, Spigel DR, Stabler JO, Tashbar J, Masters G. Hanna NH, et al. Among authors: haddad ry. J Clin Oncol. 2020 May 10;38(14):1608-1632. doi: 10.1200/JCO.19.03022. Epub 2020 Jan 28. J Clin Oncol. 2020. PMID: 31990617
Therapy for Stage IV Non-Small-Cell Lung Cancer Without Driver Alterations: ASCO Living Guideline.
Singh N, Temin S, Baker S Jr, Blanchard E, Brahmer JR, Celano P, Duma N, Ellis PM, Elkins IB, Haddad RY, Hesketh PJ, Jain D, Johnson DH, Leighl NB, Mamdani H, Masters G, Moffitt PR, Phillips T, Riely GJ, Robinson AG, Rosell R, Schiller JH, Schneider BJ, Spigel DR, Jaiyesimi IA. Singh N, et al. Among authors: haddad ry. J Clin Oncol. 2022 Oct 1;40(28):3323-3343. doi: 10.1200/JCO.22.00825. Epub 2022 Jul 11. J Clin Oncol. 2022. Update in: J Clin Oncol. 2023 Feb 10;41(5):e1-e9. doi: 10.1200/JCO.22.02121 Update in: J Clin Oncol. 2023 Apr 10;41(11):e21-e30. doi: 10.1200/JCO.22.02783 Update in: J Clin Oncol. 2023 May 20;41(15):e51-e62. doi: 10.1200/JCO.23.00282 PMID: 35816668 Updated.
Therapy for Stage IV Non-Small-Cell Lung Cancer With Driver Alterations: ASCO and OH (CCO) Joint Guideline Update.
Hanna NH, Robinson AG, Temin S, Baker S Jr, Brahmer JR, Ellis PM, Gaspar LE, Haddad RY, Hesketh PJ, Jain D, Jaiyesimi I, Johnson DH, Leighl NB, Moffitt PR, Phillips T, Riely GJ, Rosell R, Schiller JH, Schneider BJ, Singh N, Spigel DR, Tashbar J, Masters G. Hanna NH, et al. Among authors: haddad ry. J Clin Oncol. 2021 Mar 20;39(9):1040-1091. doi: 10.1200/JCO.20.03570. Epub 2021 Feb 16. J Clin Oncol. 2021. PMID: 33591844
Therapy for Stage IV Non-Small-Cell Lung Cancer With Driver Alterations: ASCO Living Guideline.
Singh N, Temin S, Baker S Jr, Blanchard E, Brahmer JR, Celano P, Duma N, Ellis PM, Elkins IB, Haddad RY, Hesketh PJ, Jain D, Johnson DH, Leighl NB, Mamdani H, Masters G, Moffitt PR, Phillips T, Riely GJ, Robinson AG, Rosell R, Schiller JH, Schneider BJ, Spigel DR, Jaiyesimi IA. Singh N, et al. Among authors: haddad ry. J Clin Oncol. 2022 Oct 1;40(28):3310-3322. doi: 10.1200/JCO.22.00824. Epub 2022 Jul 11. J Clin Oncol. 2022. Update in: J Clin Oncol. 2023 Feb 10;41(5):e10-e20. doi: 10.1200/JCO.22.02124 Update in: J Clin Oncol. 2023 Apr 10;41(11):e31-e41. doi: 10.1200/JCO.22.02782 Update in: J Clin Oncol. 2023 May 20;41(15):e42-e50. doi: 10.1200/JCO.23.00281 Update in: J Clin Oncol. 2023 Aug 20;41(24):e63-e72. doi: 10.1200/JCO.23.01055 PMID: 35816666 Updated.
Duvelisib with docetaxel for patients with anti-PD-1 refractory, recurrent or metastatic head and neck squamous cell carcinoma.
Hanna GJ, Oakley LB, Shi R, ONeill A, Shin KY, Scarfo N, Sehgal K, Dennis MJ, Quinn N, Jo VY, Wong K, Shvyrkova A, Kushnarev V, Shanthappa BU, Tkachuk A, Kryukov K, Sarachakov A, Svekolkin V, Lennerz J, Waters S, Haddad RI. Hanna GJ, et al. Among authors: haddad ri. Clin Cancer Res. 2024 Dec 3. doi: 10.1158/1078-0432.CCR-24-2262. Online ahead of print. Clin Cancer Res. 2024. PMID: 39625478
Methylation cytometric pretreatment blood immune profiles with tumor mutation burden as prognostic indicators for survival outcomes in head and neck cancer patients on anti-PD-1 therapy.
Zhang Z, Sehgal K, Shirai K, Butler RA, Wiencke JK, Koestler DC, Ramush G, Lee MK, Molinaro AM, Stolrow HG, Birnbaum A, Salas LA, Haddad RI, Kelsey KT, Christensen BC. Zhang Z, et al. Among authors: haddad ri. NPJ Precis Oncol. 2024 Nov 18;8(1):267. doi: 10.1038/s41698-024-00759-8. NPJ Precis Oncol. 2024. PMID: 39558036 Free PMC article.
1,242 results